1Sin DD,Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease [J].Circulation,2003,107(11):1514 - 1519.
2Aziz N, Fahey JL, Detels R, et al. Analytical performance of a highly sensitive C - reactive protein - based immunoassay and the effects of laboratory variables on levels of protein in blood [J]. Clin Diagn Lab Immunol,2003,10(4):652 -657.
4Verma S ,Li SH, Badiwala MV,et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C -reactive protein[J]. Circulation,2002,105(16):1890 - 1896.
3[2]Steel DM. Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum yloid A protein[J ]. Immunol Today, 1994,15:81-88.
4[1]Tillett W S, Francis T Jr.SeroIogical reactive in pneumonia with a nonprote in somatic fraction of pneum ococcus[J].J Exp Med.1930,52:561-571.
6[3]Roberts W L,Sedrick R,Moulton L,et al.Evaluation of four antomared high-senstivity C-reactive protein methods:implications for clinical and epidem iological applitations[J].Clin Chem,2000,46(4):461-468.
8[5]Erlandsen E J. Renders E.Reference in terval for serum C-reactive protein in healthy blood donors using the Date Behring N Latex CRP mono assay[J].Scand J Clin Lab Invest,2000,60(1):37-43.
9[6]ROhde L E,Hennekens C H,Ridker P M.Survey of C-reactive protin and cardiovascular risk factors in apparently healthy men[J].Am J CardioI,1999,84(9):1018-1022.
10[7]Ford E S.Body mass index,diabetes,and C-reactive protein among U S adults[J].Diabetes Care,1999,22:1971-1977.
